5147 studies found for:    vaccine
Show Display Options
Rank Status Study
1 Completed
Has Results
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
Conditions: Pneumococcal Disease.;   Meningococcal Disease.;   Streptococcus Pneumoniae Vaccines
Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: Prevenar;   Biological: Infanrix hexa;   Biological: Infanrix IPV Hib;   Biological: Infanrix penta;   Biological: Infanrix IPV;   Biological: Meningitec;   Biological: NeisVac-C;   Biological: Menitorix
2 Completed Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines
Condition: Prophylaxis of Avian Influenza Vaccine
Intervention: Biological: Fluad H5N1 Pandemic Influenza Vaccine
3 Completed
Has Results
The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines
Condition: Hepatitis b
Interventions: Biological: 60mcg/1.0ml recombinant hepatitis B vaccine;   Biological: 30mcg/1.0ml recombinant hepatitis B vaccine;   Biological: 10mcg/1.0ml recombinant hepatitis B vaccine
4 Completed Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
Condition: Plague Vaccine
Interventions: Biological: rF1V vaccine (with Adjuvant);   Biological: rF1V vaccine (without Adjuvant)
5 Completed
Has Results
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
Conditions: Encephalitis;   Japanese Encephalitis
Interventions: Biological: Japanese encephalitis chimeric virus vaccine (JE-CV);   Biological: Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)
6 Completed
Has Results
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM conjugate vaccine;   Biological: Licensed comparator
7 Recruiting Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine;   Biological: CYD Dengue and Japanese Encephalitis Vaccines;   Biological: Japanese Encephalitis and CYD Dengue Vaccines
8 Completed
Has Results
Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old
Condition: Influenza
Interventions: Biological: Lot A of Influenza virus vaccine;   Biological: Lot B of Influenza virus vaccine;   Biological: Lot C of Influenza virus vaccine;   Biological: Comparator influenza virus vaccine;   Biological: All 3 consecutive lots of influenza virus vaccine pooled
9 Completed Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever;   Yellow Fever
Interventions: Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus;   Biological: Yellow fever vaccine;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal Conjugated Vaccine;   Biological: Hepatitis A Pediatric Vaccine;   Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine;   Biological: Yellow Fever Vaccine;   Biological: Placebo (NaCl)
10 Active, not recruiting Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever;   Yellow Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus;   Biological: Yellow Fever + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus;   Biological: Yellow Fever
11 Completed
Has Results
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
Condition: Influenza
Interventions: Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV);   Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV);   Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV);   Biological: Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)
12 Completed Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to 72 Months) Versus Control Vaccines
Condition: Influenza Disease
Interventions: Biological: Adjuvanted trivalent inactivated subunit influenza vaccine;   Biological: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine;   Biological: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
13 Completed
Has Results
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
Conditions: 13-valent Pneumococcal Vaccine;   Immunization;   Safety;   Antibody Response
Intervention: Biological: 13-valent pneumococcal conjugate vaccine
14 Completed
Has Results
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
Condition: Pandemic Influenza Disease
Interventions: Biological: Placebo;   Biological: Trivalent influenza virus vaccine (TIV);   Biological: Adjuvanted monovalent influenza virus vaccine (aH5N1);   Biological: Adjuvanted trivalent influenza vaccine (aTIV)
15 Completed Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
Condition: Influenza
Interventions: Biological: DNA vaccine;   Biological: TIV
16 Active, not recruiting Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years
Condition: Influenza
Interventions: Biological: Seasonal Influenza DNA vaccine;   Biological: TIV
17 Completed
Has Results
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Haemophilus Infections
Interventions: Biological: DTaP-HB-PRP~T vaccine + OPV;   Biological: Tritanrix-HepB/Hib™ + OPV vaccine;   Biological: Oral Polio Vaccine
18 Completed
Has Results
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation;   Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal;   Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
19 Completed Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
Condition: Staphylococcal Infections
Interventions: Biological: SA4Ag vaccine low dose;   Procedure: Blood draw;   Procedure: Colonization swab sample;   Biological: SA4Ag vaccine mid dose;   Biological: SA4Ag vaccine high dose;   Biological: SA3Ag vaccine;   Procedure: Blood sample;   Biological: Placebo;   Procedure: Colonization swab samples
20 Completed
Has Results
Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
Condition: Vaccine Response Impaired
Interventions: Biological: Tetanus & Diphtheria booster vaccine (Td);   Biological: TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine];   Biological: Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years